Drug Profile
F-Spondin
Latest Information Update: 15 Oct 2002
Price :
$50
*
At a glance
- Originator CeNeS Pharmaceuticals
- Class Growth factors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 15 Oct 2002 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
- 02 Jul 2001 No-Development-Reported for Spinal cord injuries in USA (Unknown route)
- 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals